Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double-blind, Multicentre, Placebo Controlled, Parallel Group Design to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

NCT06402630 is registered in ClinicalTrials.gov with Soterios Ltd as lead sponsor.

NCT NCT06402630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06402630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double-blind, Multicentre, Placebo Controlled, Parallel Group Design to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
Lead sponsor
Soterios Ltd
Phase
Phase 2
Overall status
Completed
Start date
March 23, 2022
Completion date
April 1, 2024
Enrollment
158 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata